Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis

Vyome Holdings, Inc

2026-Q1 EPS reported -$0.15 vs consensus -$0.18 ▲ beat (+18.3%)

Net loss of approx. $963K ($0.15 per share) for Q1 ended March 31, 2026.
Cash and equivalents $8.8M, up from $5.0M at Dec 31, 2025; no debt or toxic financing.
In-licensed two selective JAK inhibitor assets from Impetis Biosciences (TATA Enterprise) for global ~$57B market.
Filed Orphan Drug Designation application for VT-1953 with FDA; submitted proposals for pivotal development guidance.
Raised $5.29M via sale of 1,089,545 shares at $5.00 (59.2% premium to prior close); ~15% dilution.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Vyome Holdings, Inc reported first quarter ended March 31, 2026 results: net income Net loss attributable to common shareholders for the quarter ended March 31, 2026, was approximately $963,000, or approx, EPS approximately $0.15 per basic and diluted share.

Period: first quarter ended March 31, 2026
Net income: Net loss attributable to common shareholders for the quarter ended March 31, 2026, was approximately $963,000, or approx
EPS: approximately $0.15 per basic and diluted share
Result: reported results

Exact text from the filing

Vyome Holdings, Inc. issued a press release announcing its financial results for its first fiscal quarter ended March 31, 2026.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001213900-26-062458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.